AlphAIAlphAI — Financial news for AI agents
stocktitan.netAUG 211 min read$ARDX

Ardelyx (NASDAQ: ARDX) plans RSU tax-cover sale of 10,500 shares

Ardelyx (ARDX) filed a notice under Rule 144 for a potential sale of 10,500 shares by Laura A. Williams to cover taxes on vesting RSUs. The shares have an aggregate market value of $42,315. The sale is part of an automatic sell-to-cover mechanism for withholding taxes on 24,041 RSUs vesting in August 2026.

Original reporting
stocktitan.net
Published Aug 21, 2026, 11:38 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Aug 22, 2026, 1:23 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
AlphAI market briefCorporate actions
Primary signal
$ARDX
Neutral
high confidence
Mentioned
$ARDX
Relevance
5/10
AlphAI data visualization · based on stocktitan.net
Decision brief

The 30-second read

$ARDXNeutralLow
01

Why it matters

The disclosed sale is routine and unlikely to affect the stock significantly.

02

Market read

Limited impact; typical insider tax‑cover transaction.

03

What to watch

Potential future RSU vestings could increase supply.

Relevance 5/10Novelty 6/10Timing: recent filing

Background

Ardelyx filed a Rule 144 notice for a tax‑cover sale of shares related to a recent RSU vesting.

Company-level read

Ticker impact

$ARDXNeutralHigh confidence
Context

Form 144 filing discloses a sell‑to‑cover of 10,500 shares to cover taxes on RSU vesting.

Expected impact

minimal downward pressure

Evidence & confidence

Small transaction relative to float; typical tax‑cover sale.

Market effects

Sector

None

Regional

None

Global

None

Counterpoint

What could challenge this read

The filing may signal insider confidence despite the sell‑to‑cover.

Key entities

  • Insider
    Laura A. Williams

    Officer/director selling shares to cover tax withholding.

Read at source← All news

Related articles

OCT 12
$ARDXMedAI 8/10

Ardelyx reports drop in healthcare visits after IBS-C treatment

Ardelyx Inc. (ARDX) reported data showing a reduction in gastrointestinal-related healthcare visits among IBS-C patients after treatment with IBSRELA (tenapanor). The analysis of 470 patients showed a median decrease from 4.5 to 3.0 visits per year. The findings were presented at the American College of Gastroenterology 2026 Annual Scientific Meeting. Ardelyx also shared data on IBS-C symptom burden and an ongoing Phase 3 study for chronic idiopathic constipation.

investing.com2 min
AUG 14
$ARDXMedAI 8/10

Ardelyx (ARDX) Q2 2026 Earnings Call Transcript

Ardelyx (ARDX) reported Q2 2026 product revenue of $118.1 million, up 31% year over year, driven by IBSRELA ($86.2 million, +33%) and XPHOZAH ($31.9 million, +27%). Net loss was $16.7 million. The company revised 2026 guidance to $350-$370 million for IBSRELA and $110-$120 million for XPHOZAH, citing payer hurdles.

fool.com6 min
AUG 7
$ARDXHighAI 9/10

Why is Ardelyx stock plunging today?

Ardelyx (ARDX) shares fell about 16% pre-open after the company reported Q2 2026 results that missed Wall Street on revenue and EPS and cut full-year guidance. Q2 total product revenue was $118.1M, net loss $16.7M (-$0.07/share). Ardelyx lowered 2026 IBSRELA revenue guidance to $350–$370M and withdrew a prior XPHOZAH long-term target.

investing.com4 min
AUG 6
$ARDXMed

Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update

ARDELYX, INC. (ARDX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Ardelyx Reports Second Quarter 2026 Financial Results and Provides Business Update Q2 2026 total product revenue of $118.1 million, reflecting 31% growth year-over-year IBSRELA Q2 2026 revenue growth of 33% year-over-year to $86.2 million XPHOZAH Q2 2026 revenue grow

SEC EDGAR 8-K5 min